NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased securities of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT) between February 5, 2021 and May 14, 2024, inclusive (the "Class Period").
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or commercial prospects of ...
BOLT)>Full story available on Benzinga.com